Montreal-based Caprion has established itself as a leader in the proteomic biomarker discovery field, using its proteomics discovery platform CellCarta® to develop pharmacodynamic biomarkers, disease markers and predictive biomarkers. OneMedRadio spoke with Caprion President and CEO Martin Leblanc about industry trends concerning increased risk factors, securing intellectual property and developing an in vitro diagnostics platform.
This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
September is Sickle Cell Awareness Month, a time when the medical community will gather with the patient population in the hopes of advancing research in this significant unmet medical need. One company, ADVENTRX Pharmaceuticals [NYSE: ANX], is attempting to engage the investor community and the sector’s most promising drug developers through the First Annual Sickle Cell Disease Therapeutics Conference, taking place September 19th, 2012 in New York City.
In Part III of our interview with Dr. Qin Shi of Edgetech Law we visit the concept of human genome sequencing as a mainstream commodity.
In Part II of our special interview series, Dr. Qin Shi of Edgetech Law discusses the emerging areas of significant unmet need in life science, and what investment opportunities may arise.
Part two of our Special Report highlight an important case that may significantly affect the patent infringement landscape. Shares of Myriad Genetics fell 10 percent in the wake of the Mayo ruling.